References
- Feng, Y.; Spezia, M.; Huang, S.; Yuan, C.; Zeng, Z.; Zhang, L.; Ji, X.; Liu, W.; Huang, B.; Luo, W.; et al. Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis. Genes Dis. 2018, 5, 77–106. DOI: https://doi.org/10.1016/j.gendis.2018.05.001.
- Guo, M.; Peng, Y.; Gao, A.; Du, C.; Herman, J. G. Epigenetic Heterogeneity in Cancer. Biomark. Res 2019, 7, 1–19.
- Masoud, V.; Pagès, G. Targeted Therapies in Breast Cancer: New Challenges to Fight against Resistance. World J Clin Oncol. 2017, 8, 120–134. DOI: https://doi.org/10.5306/wjco.v8.i2.120.
- Chen, L.; Zeng, T.; Pan, X.; Zhang, Y.-H.; Huang, T.; Cai, Y.-D. Identifying Methylation Pattern and Genes Associated with Breast Cancer Subtypes. IJMS. 2019, 20, 4269. DOI: https://doi.org/10.3390/ijms20174269.
- Mei, J.; Zhao, J.; Fu, Y. Molecular Classification of Breast Cancer Using the MRNA Expression Profiles of Immune-Related Genes. Sci. Rep. 2020, 10, 1–9.
- Onitilo, A. A.; Engel, J. M.; Greenlee, R. T.; Mukesh, B. N. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin. Med. Res. 2009, 7, 4–13. DOI: https://doi.org/10.3121/cmr.2008.825.
- Reddy, S. M.; Barcenas, C. H.; Sinha, A. K.; Hsu, L.; Moulder, S. L.; Tripathy, D.; Hortobagyi, G. N.; Valero, V. Long-Term Survival Outcomes of Triple-Receptor Negative Breast Cancer Survivors Who Are Disease Free at 5 Years and Relationship with Low Hormone Receptor Positivity. Br. J. Cancer. 2018, 118, 17–23. DOI: https://doi.org/10.1038/bjc.2017.379.
- Mehanna, J.; Haddad, F. G. H.; Eid, R.; Lambertini, M.; Kourie, H. R. Triple-Negative Breast Cancer: Current Perspective on the Evolving Therapeutic Landscape. Int. J. Womens. Health. 2019, 11, 431–437. DOI: https://doi.org/10.2147/IJWH.S178349.
- Gaibar, M.; Beltrán, L.; Romero-Lorca, A.; Fernández-Santander, A.; Novillo, A. Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer. J. Oncol 2020, 2020.
- Group, E. B. C. T. C. Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials. Lancet 2011, 378, 771–784.
- Chang, M. Tamoxifen Resistance in Breast Cancer. Biomol Ther (Seoul). 2012, 20, 256–267. DOI: https://doi.org/10.4062/biomolther.2012.20.3.256.
- Costa, R. L. B.; Czerniecki, B. J. Clinical Development of Immunotherapies for HER2+ Breast Cancer: A Review of HER2-Directed Monoclonal Antibodies and Beyond. NPJ Breast Cancer. 2020, 6, 10–11. DOI: https://doi.org/10.1038/s41523-020-0153-3.
- Holmes, F. A. Paclitaxel Combination Therapy in the Treatment of Metastatic Breast Cancer: A Review. Semin. Oncol. 1996, 23, 46–56. pp
- Collignon, J.; Lousberg, L.; Schroeder, H.; Jerusalem, G. Triple-Negative Breast Cancer: Treatment Challenges and Solutions. Breast Cancer (Dove Med Press). 2016, 8, 93–107. DOI: https://doi.org/10.2147/BCTT.S69488.
- Colaprico, A.; Silva, T. C.; Olsen, C.; Garofano, L.; Cava, C.; Garolini, D.; Sabedot, T. S.; Malta, T. M.; Pagnotta, S. M.; Castiglioni, I.; et al. TCGAbiolinks: An R/Bioconductor Package for Integrative Analysis of TCGA Data. Nucleic Acids Res. 2016, 44, e71. DOI: https://doi.org/10.1093/nar/gkv1507.
- Robinson, M. D.; McCarthy, D. J.; Smyth, G. K. EdgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. Bioinformatics 2010, 26, 139–140. DOI: https://doi.org/10.1093/bioinformatics/btp616.
- Ritchie, M. E.; Phipson, B.; Wu, D. I.; Hu, Y.; Law, C. W.; Shi, W.; Smyth, G. K. Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. Nucleic Acids Res. 2015, 43, e47. DOI: https://doi.org/10.1093/nar/gkv007.
- Kuleshov, M. V.; Jones, M. R.; Rouillard, A. D.; Fernandez, N. F.; Duan, Q.; Wang, Z.; Koplev, S.; Jenkins, S. L.; Jagodnik, K. M.; Lachmann, A.; et al. Enrichr: A Comprehensive Gene Set Enrichment Analysis Web Server 2016 Update. Nucleic Acids Res. 2016, 44, W90–W97. DOI: https://doi.org/10.1093/nar/gkw377.
- Dai, X.; Cheng, H.; Bai, Z.; Li, J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J. Cancer 2017, 8, 3131–3141. DOI: https://doi.org/10.7150/jca.18457.
- Nedeljković, M.; Damjanović, A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. Cells 2019, 8, 957. DOI: https://doi.org/10.3390/cells8090957.
- Dong, P.; Yu, B.; Pan, L.; Tian, X.; Liu, F. Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis. Biomed Res. Int. 2018, 2018, 1–10. DOI: https://doi.org/10.1155/2018/2760918.
- Kim, J.; Yu, D.; Kwon, Y.; Lee, K. S.; Sim, S. H.; Kong, S.-Y.; Lee, E. S.; Park, I. H.; Park, C. Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response. Mol. Cancer Res. 2020, 18, 253–263.
- Wang, X.; Guda, C. Integrative Exploration of Genomic Profiles for Triple Negative Breast Cancer Identifies Potential Drug Targets. Medicine. (Baltimore). 2016, 95, e4321. DOI: https://doi.org/10.1097/MD.0000000000004321.
- Gong, Y.; Ji, P.; Yang, Y. S.; Xie, S.; Yu, T. J.; Xiao, Y.; Jin, M. L.; Ma, D.; Guo, L. W.; Pei, Y. C.; et al. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab. 2021, 33, 51–64.e9. DOI: https://doi.org/10.1016/j.cmet.2020.10.012.
- Liu, Q.; Zhou, X.; Li, C.; Zhang, X.; Li, C. L. Rapamycin Promotes the Anticancer Action of Dihydroartemisinin in Breast Cancer MDA-MB-231 Cells by Regulating Expression of Atg7 and DAPK. Oncol. Lett. 2018, 15, 5781–5786.
- Alayev, A.; Berger, S. M.; Kramer, M. Y.; Schwartz, N. S.; Holz, M. K. The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells. J. Cell. Biochem. 2015, 116, 450–457. DOI: https://doi.org/10.1002/jcb.24997.
- Liu, T.; Yacoub, R.; Taliaferro-Smith, L. D.; Sun, S.-Y.; Graham, T. R.; Dolan, R.; Lobo, C.; Tighiouart, M.; Yang, L.; Adams, A.; O’Regan, R. M. Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells. Mol. Cancer Ther. 2011, 10, 1460–1469. DOI: https://doi.org/10.1158/1535-7163.MCT-10-0925.
- Sun, X.; Wang, M.; Wang, M.; Yu, X.; Guo, J.; Sun, T.; Li, X.; Yao, L.; Dong, H.; Xu, Y. Metabolic Reprogramming in Triple-Negative Breast Cancer. Front. Oncol. 2020, 10, 428. DOI: https://doi.org/10.3389/fonc.2020.00428.
- Metcalf, S.; Kruer, T.; Dougherty, S.; Biyik-Sit, R.; Klinge, C.; Clem, B. The Role of PSAT1 in Triple Negative Breast Cancer Metastasis. AACR 2019.